临床外科杂志 ›› 2022, Vol. 30 ›› Issue (9): 823-828.doi: 10.3969/j.issn.1005-6483.2022.09.007

• 论著 • 上一篇    下一篇

术前化疗后行细胞减灭术联合腹腔热灌注化疗治疗结直肠癌腹膜转移的安全性及疗效分析

  

  1. 101400 北京市怀柔区中医医院外科(吴国庆);国家癌症中心/国家肿瘤临床医学研究中心/中国医学科学院北京协和医学院肿瘤医院结直肠外科(周思成,陈海鹏,郑朝旭, 周海涛, 裴炜, 梁建伟);桓兴肿瘤医院腹部外科(张景)
  • 收稿日期:2022-05-11 接受日期:2022-05-11 出版日期:2022-09-20 发布日期:2022-10-14
  • 通讯作者: 裴炜,Email:peiweifbwk@163.com
  • 基金资助:
    中国癌症基金会北京希望马拉松专项基金(LC2020A37)

Safety and efficacy of cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy in the treatment of peritoneal metastases in colorectal cancer after preoperative chemotherapy

  1. Department of General Surgery,Beijing Huairou District Hospital of Traditional Chinese medicine,Beijing 101400,China
  • Received:2022-05-11 Accepted:2022-05-11 Online:2022-09-20 Published:2022-10-14

摘要: [摘要] 目的 评价细胞减灭术(cytoreductive surgery,CRS)联合腹腔热灌注化疗(hyperthermic intraperitoneal chemotherapy,HIPEC)前应用术前化疗治疗同时性结直肠癌腹膜转移的安全性和有效性 方法 2017年6月~2019年6月在国家癌症中心和桓兴肿瘤医院接受CRS+HIPEC治疗同时性结直肠癌腹膜转移病人52例,根据有无接受术前化疗,将病人分为术前化疗组(20例)和未术前化疗组(32例)。结果 在术前化疗组,腹膜癌指数(peritoneal carcinomatosis index,PCI)>12的病人比例显著高于未术前化疗组(80.0% 和50.0%,P=0.031),更多的病人实现了完全CRS(80.0% 和46.9%,P=0.018)。两组病人Ⅲ/Ⅳ级并发症发生率、再手术率和死亡率比较,差异无统计学意义(P>0.05)。接受术前化疗的病人术后第1天血小板计数(151.9 ×109/L和197.7×109/L,P=0.036)和白细胞计数(4.7 ×109/L和7.2×109/L,P=0.030)明显较低。术前化疗组存活超过2年的病人比例明显大于未术前化疗组(67.4% 和32.2%,P=0.044)。多因素分析显示,CRS评分(HR,2.99,95%CI,1.14 ~7.84,P=0.026)是影响总生存率的独立危险因素,而非术前化疗。结论 对于结直肠癌腹膜转移病人,CRS+HIPEC前进行术前化疗是安全可行的,有着相对较低的并发症发生率和死亡率。

关键词: 细胞减灭术, 腹腔热灌注化疗, 结直肠癌, 腹膜转移, 术前化疗

Abstract: [Abstract] Objective To evaluate the perioperative safety and long-term efficacy of preoperative in patients with simultaneous colorectal peritoneal metastasis before CRS+HIPEC.Methods This study retrospectively analyzed patients who received preoperative chemotherapy combined with CRS+HIPEC for simultaneous colorectal peritoneal metastasis in National Cancer Center and Huanxing Cancer Hospital from June 2017 to June 2019.A total of 52 patients were included in this study,and they were divided into preoperative chemotherapy group(n=20) and non-preoperative chemotherapy group(n=32) according to whether or not they had received preoperative chemotherapy.Results In the preoperative chemotherapy group,the proportion of patients with a peritoneal carcinomatosis index(PCI) >12 was significantly higher than in the non-preoperative chemotherapy group(80.0% vs.50.0%,P=0.031),while more patients achieved complete cytoreductives(80.0% vs 46.9%,P=0.018).There were no significant differences in the incidence of grade Ⅲ/Ⅳ complications,reoperation rates and mortality rates between the two groups(P>0.05).Platelet counts(151.9 ×109/L和197.7×109/L,P=0.036) and white blood cell count(4.7 ×109/L和7.2×109/L,P=0.030) were significantly lower on the first day after surgery in patients receiving preoperative chemotherapy.Patients in the preoperative group survived more than 2 years significantly more than those in the nonpreoperative group(67.4% vs 32.2%,P=0.044).Multivariate analysis showed that completeness of the cytoreduction score(HR,2.99;95% CI,1.14~7.84;P=0.026) was an independent risk factor for overall survival,but not preoperative chemotherapy.Conclusion For patients with peritoneal metastasis of colorectal cancer,preoperative chemotherapy before CRS+HIPEC is safe and feasible,with a relatively low incidence of complications and mortality.

Key words: cytoreductive surgery, hyperthermic intraperitoneal chemotherapy, colorectal cancer, peritoneal metastasis, preoperative chemotherapy

[1] 李博文 韩元圣 黄高俊 郑磊. 微小RNA-370-3p和Toll样受体4在结直肠癌组织中的表达及临床意义[J]. 临床外科杂志, 2022, 30(9): 860-864.
[2] 吴永力 方汉刚 陈静 闫瑞承. 术前外周血微小RNA-21、血管内皮生长-因子、糖类抗原19-9水平与JP3结直肠癌病人临床分期和术后复发转移的关系[J]. 临床外科杂志, 2022, 30(8): 771-774.
[3] 任俊 吴敬 金田力 付涛. 长链非编码RNA在结直肠癌中的诊断价值和作用机制[J]. 临床外科杂志, 2022, 30(6): 596-599.
[4] 刘永斌 王成 刘延杰 刘芳 岳萌 吕菲 刘广杰 王贵英. 转钴胺1在结直肠癌及其肺转移组织中的表达及临床意义[J]. 临床外科杂志, 2022, 30(1): 54-57.
[5] 宋伟 袁文正 任俊 付涛. 环状RNA的研究现状及其与结直肠癌的相关[J]. 临床外科杂志, 2022, 30(1): 95-98.
[6] 陈建军, 王振军, 赵宝成等. 黑色素瘤缺乏因子2在结直肠癌中的表达及临床意义[J]. 临床外科杂志, 2021, 29(8): 751-753.
[7] 李晶 赵宝成 王振军. 加速康复外科理念下结直肠癌围手术期营养支持治疗[J]. 临床外科杂志, 2021, 29(7): 693-695.
[8] 侯松林, 谢兴江, 彭强等. 结直肠癌肝转移病人原发灶切除的临床意义及其预后影响因素分析——基于SEER数据库的倾向得分匹配分析[J]. 临床外科杂志, 2021, 29(6): 543-548.
[9] 龙飞 胡桂 马敏 李小荣. 2021.V1版NCCN临床实践指南:结肠癌/直肠癌更新解读(外科部分)[J]. 临床外科杂志, 2021, 29(5): 401-404.
[10] 冯青阳 许剑民. 机器人结直肠癌手术中国专家共识(2020版)解读[J]. 临床外科杂志, 2021, 29(5): 405-408.
[11] 隋金珂 张卫. 腹腔镜结直肠手术的现状[J]. 临床外科杂志, 2021, 29(5): 492-494.
[12] 王海娟 郑雅宾 张静. Skp2/p27轴在结直肠癌发生发展中的作用机制研究[J]. 临床外科杂志, 2021, 29(11): 1054-1058.
[13] 练磊 兰平. 国家卫健委中国结直肠癌诊疗规范解读(2020 版)——外科部分[J]. 临床外科杂志, 2021, 29(1): 10-12.
[14] 吴川清, 李源, 王点石, 杜周元, 吴轲, 高金波, 王征, 王国斌, 陶凯雄. 腹腔热灌注化疗治疗胃癌腹膜转移的安全性及有效性单中心临床研究[J]. 临床外科杂志, 2020, 28(5): 424-428.
[15] 曹英豪, 吴轲, 古俊楠等. 晚期结肠癌病人姑息性支架置入的应用效果研究[J]. 临床外科杂志, 2020, 28(5): 429-432.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
[1] 昌盛. 中国心脏死亡捐献供肾器官的维护[J]. 临床外科杂志, 2016, 24(10): 744 .
[2] 石宇;刘学刚 . 冠状动脉旁路移植术后短期内应用强化他汀对患者出血风险的研究[J]. 临床外科杂志, 2016, 24(10): 750 .
[3] 阿布力克木·毛拉尤甫;郑秉礼. 胰腺实性假乳头状瘤45例手术治疗分析[J]. 临床外科杂志, 2016, 24(10): 764 .
[4] 胡志伟;汪忠镐;张玉;等. 腹腔镜Toupet胃底折叠术治疗干燥综合征合并严重胃食管反流病两例[J]. 临床外科杂志, 2016, 24(10): 766 .
[5] 李义亮;张成;克力木;等. 完全腹腔镜下远端胃癌根治术的临床体会[J]. 临床外科杂志, 2016, 24(10): 769 .
[6] 李光焰;张安平;王祥峰;等. 直肠癌切除术后吻合口狭窄14例分析[J]. 临床外科杂志, 2016, 24(10): 772 .
[7] 张忠伟;刘扬;路明. 痔上黏膜环切术治疗直肠前突所致出口梗阻型便秘的疗效观察[J]. 临床外科杂志, 2016, 24(10): 774 .
[8] 肖国栋;刘国辉. 跗骨窦切口联合经皮置钉技术微创治疗跟骨骨折的临床疗效分析[J]. 临床外科杂志, 2016, 24(10): 783 .
[9] 陈绍站;许勇;李婧;等. 防旋股骨近端髓内针与股骨近端解剖锁定钢板治疗转子间骨折的疗效比较[J]. 临床外科杂志, 2016, 24(10): 787 .
[10] 戴强;徐康;周治军;等. 湖北天门地区泌尿系结石成分及特征分析[J]. 临床外科杂志, 2016, 24(10): 789 .